Literature DB >> 7272590

Morphine-theophylline interaction: antagonism or facilitation?

S Brailowsky, F Guerrero-Muñoz, M Luján, M Shkurovich.   

Abstract

1 Morphine-theophylline interactions were investigated in both acute and narcotic-dependent preparations, in vitro and in vivo, using four different experimental models: LD50 doses of morphine and naloxone in the mouse; naloxone-induced contractions in the electrically-stimulated and opiate-dependent isolated ileum of the guinea-pig; naloxone-induced jumps in the mouse; an calcium uptake in synaptosomal preparations. 2 The LD50 of morphine was significantly increased by theophylline. 3 The lethal effect of theophylline was potentiated by pretreatment of the animals with naloxone. 4 Theophylline displayed protective effects in the inhibitory response to morphine and antagonism to the withdrawal response induced by naloxone in the electrically-stimulated isolated ileum of the guinea-pig. 5 The number of jumps induced by naloxone in morphine-dependent mice was significantly diminished by theophylline. 6 The inhibitory effect of morphine on the synaptosomal uptake of calcium was decreased by theophylline. 7 The effects of both morphine and theophylline on the cyclic nucleotides and the possible role of calcium in these actions are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7272590      PMCID: PMC2071489          DOI: 10.1111/j.1476-5381.1981.tb08742.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

Review 1.  Commentary: Brain calcium and morphine action.

Authors:  I S Sanghvi; S Gershon
Journal:  Biochem Pharmacol       Date:  1977-07-01       Impact factor: 5.858

Review 2.  Relationships between calcium and cyclic nucleotides in cell activation.

Authors:  H Rasmussen; D B Goodman
Journal:  Physiol Rev       Date:  1977-07       Impact factor: 37.312

3.  Effect of cyclic nucleotides and phosphodiesterase inhibition on morphine tolerance and physical dependence.

Authors:  L K Ho; H H Loh; H N Bhargava; E L Way
Journal:  Life Sci       Date:  1975-06-15       Impact factor: 5.037

4.  Effect of beta-endorphin on calcium uptake in the brain.

Authors:  F Guerrero-Munoz; M de Lourdes Guerrero; E L Way; C H Li
Journal:  Science       Date:  1979-10-05       Impact factor: 47.728

5.  Cyclic adenosine monophosphate antagonism of morphine analgesia.

Authors:  I K Ho; H H Loh; E L Way
Journal:  J Pharmacol Exp Ther       Date:  1973-05       Impact factor: 4.030

6.  Synaptic plasma membranes from rat brain synaptosomes: isolation and partial characterization.

Authors:  C W Cotman; D A Matthews
Journal:  Biochim Biophys Acta       Date:  1971-12-03

7.  Circannual variation in sensitivity of the guinea-pig isolated ileum to naloxone.

Authors:  R Rodríguez; M Luján; E Vargas-Ortega
Journal:  J Pharm Pharmacol       Date:  1980-05       Impact factor: 3.765

8.  Experimental studies on the effective procedure to inhibit the development of tolerance to and dependence on morphine.

Authors:  K Matsuda
Journal:  Arzneimittelforschung       Date:  1970-10

9.  Respiratory and cardiovascular effects of met-enkephalin applied to the ventral surface of the brain stem.

Authors:  J Flórez; A Mediavilla
Journal:  Brain Res       Date:  1977-12-23       Impact factor: 3.252

10.  Interactions of methylxanthines, nonxanthine phosphodiesterase inhibitors, and calcium with morphine in the guinea pig myenteric plexus.

Authors:  J Sawynok; K Jhamandas
Journal:  Can J Physiol Pharmacol       Date:  1979-08       Impact factor: 2.273

View more
  2 in total

1.  Adenosine receptor agonists attenuate and adenosine receptor antagonists exacerbate opiate withdrawal signs.

Authors:  G B Kaplan; M T Sears
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

2.  Antagonism of enkephalin action on acetylcholine release by methylxanthines: lack of a purine link.

Authors:  J Elliott; K Jhamandas; H Notman; M Sutak
Journal:  Br J Pharmacol       Date:  1983-12       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.